Evidence map›Paper›PMID 39472381›Full record

ArticleAbdominal radiology (New York)2025

Diagnostic significance of peritumoral enhancement in distinguishing between muscle-invasive and non-muscle-invasive bladder cancer.

Mitsuru Takeuchi, Atsushi Higaki, Yuichi Kojima, Kentaro Ono, Takuma Maruhisa, Takatoshi Yokoyama, Hiroyuki Watanabe, Akira Yamamoto, Tsutomu Tamada

Abstract read
PubMed Publisher
In one paragraph

Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Current Status and Future Perspective for Bladder Cancer MR Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in Japan: Challenges and Solutions.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026
    Review
  2. Histopathological Basis of Peritumoral Enhancement in Muscle-invasive Bladder Cancer.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026
    Article
  3. What's next for VI-RADS? Updates and future perspectives from the ACR VI-RADS steering committee.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mitsuru TakeuchiRadiolonet Tokai, Nagoya, Japan. m2rbimn@gmail.com.
Atsushi HigakiKawasaki Medical School, Kurashiki, Japan.
Yuichi KojimaKawasaki Medical School, Kurashiki, Japan.
Kentaro OnoKawasaki Medical School, Kurashiki, Japan.
Takuma MaruhisaKawasaki Medical School, Kurashiki, Japan.
Takatoshi YokoyamaKawasaki Medical School, Kurashiki, Japan.
Hiroyuki WatanabeKawasaki Medical School, Kurashiki, Japan.
Akira YamamotoKawasaki Medical School, Kurashiki, Japan.
Tsutomu TamadaKawasaki Medical School, Kurashiki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to assess the prevalence of peritumoral enhancement (PTE) in patients with muscle-invasive bladder cancer (MIBC) and non-MIBC (NMIBC) and to propose a modified diagnostic criterion for Vesical Imaging Reporting and Data System (VI-RADS) that incorporates PTE. MATERIALS AND

methodsThis retrospective study included 95 patients with bladder cancer (age, 72 ± 11; 77 men; 36 MIBCs and 59 Non-MIBCs) who underwent multiparametric MRI in our referral center between 2011 and 2023. The images were interpreted by four radiologists. The readers classified the possibility of muscle layer invasion into categories 1-5, based on the VI-RADS categorical diagnostic criterion. PTE was defined as a linear contrast enhancement observed at the edge of tumor invasion which is convex outward from the normal bladder wall and contrasts more than the normal muscle layer and tumor. A modified VI-RADS that upgrades the final VI-RADS category to 4 if PTE is present when the original VI-RADS category is 3 or less was proposed. The frequency of PTE in the MIBC and NMIBC groups was compared using the Fisher's exact test. Sensitivity and specificity for the diagnosis of MIBC were compared with the original VI-RADS using McNemar test. Pathologic diagnosis was used as the reference standard.

resultsPTE was present in 70-81% (25/36-29/36) of MIBC and absent in 92-98% (54/59-58/59) of non-MIBC. For all readers, the PTE was significantly more frequent (p < 0.001) in the MIBC group than the NMIBC group. The sensitivities of modified VI-RADS (75.0-86.1%) were significantly higher than those of original VI-RADS (41.7-55.6%) (p = 0.002-0.008). The specificity of modified VI-RADS (91.5-98.3%) were not statistically different from original VI-RADS (98.3-100%).

conclusionsIn conclusion, PTE is a highly specific finding for MIBC. modified VI-RADS incorporating PTE increases sensitivity for MIBC.

Indexed as

Image EnhancementMagnetic Resonance ImagingMultiparametric Magnetic Resonance ImagingUrinary Bladder NeoplasmsAgedAged, 80 and overContrast MediaDiagnosis, DifferentialFemaleHumansMaleMiddle AgedNeoplasm InvasivenessNon-Muscle Invasive Bladder NeoplasmsRetrospective StudiesSensitivity and SpecificityContrast MediaDynamic contrast-enhanced imagingMultiparametric magnetic resonance imagingperitumoral enhancementUrinary bladder neoplasmsVI-RADS

Identifiers

PMID39472381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.